Tilray Brands (TLRY) to Release Earnings on Thursday

Key Points

• Tilray Brands will release its Q2 2026 results after the market closes on Thursday, January 8 at 4:30 PM ET, and analysts expect a loss of ($0.17) per share on revenue of about $211.15 million.
• TLRY opened at $9.03 with a market cap near $1.01 billion and a 52‑week range of $3.51–$23.20; Wall Street's consensus rating is "Hold" with a $20.00 target (two Buys, four Holds, one Sell).

Tilray Brands (NASDAQ:TLRY - Get Free Report) is expected to be releasing its Q2 2026 results after the market closes on Thursday, January 8th. Analysts expect Tilray Brands to post earnings of ($0.17) per share and revenue of $211.1480 million for the quarter. Individuals may review the information on the company's upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, January 8, 2026 at 4:30 PM ET.

Tilray Brands Stock Performance

NASDAQ:TLRY opened at $9.03 on Thursday. The stock's fifty day moving average is $10.77 and its 200 day moving average is $10.32. Tilray Brands has a fifty-two week low of $3.51 and a fifty-two week high of $23.20. The firm has a market capitalization of $1.01 billion, a PE ratio of -0.40 and a beta of 1.76. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.56 and a current ratio of 2.62.

Wall Street Analysts Forecast Growth

TLRY has been the topic of a number of analyst reports. Wall Street Zen upgraded shares of Tilray Brands from a "strong sell" rating to a "hold" rating in a research report on Saturday, October 11th. Atb Cap Markets raised shares of Tilray Brands from a "strong sell" rating to a "hold" rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Tilray Brands in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $20.00.

Institutional Trading of Tilray Brands

Large investors have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC grew its holdings in shares of Tilray Brands by 33.8% in the third quarter. Integrated Wealth Concepts LLC now owns 36,977 shares of the company's stock worth $64,000 after purchasing an additional 9,341 shares during the last quarter. National Bank of Canada FI boosted its position in Tilray Brands by 334.5% in the 3rd quarter. National Bank of Canada FI now owns 43,445 shares of the company's stock valued at $75,000 after buying an additional 33,446 shares during the period. Ameriprise Financial Inc. grew its stake in Tilray Brands by 45.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 67,222 shares of the company's stock worth $116,000 after acquiring an additional 20,974 shares in the last quarter. CreativeOne Wealth LLC grew its stake in Tilray Brands by 12.2% in the 3rd quarter. CreativeOne Wealth LLC now owns 87,134 shares of the company's stock worth $151,000 after acquiring an additional 9,452 shares in the last quarter. Finally, Cerity Partners LLC increased its position in shares of Tilray Brands by 98.5% during the second quarter. Cerity Partners LLC now owns 92,560 shares of the company's stock worth $38,000 after acquiring an additional 45,929 shares during the period. 9.35% of the stock is owned by hedge funds and other institutional investors.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray's product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.